HBC Immunology Inc., Menlo Park, CA 2043, USA.
Hofseth BioCare, 6003 Ålesund, Norway.
Mar Drugs. 2024 Oct 30;22(11):490. doi: 10.3390/md22110490.
This study examines the in vitro effects of a soluble protein hydrolysate (SPH) derived from Atlantic salmon (Salmo salar) on incretin receptor activity and pancreatic islet cell protection to explore the mechanisms underlying SPH's observed benefits on weight loss and metabolic health in overweight individuals. SPH demonstrated a dose-dependent enhancement of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor activity, with significant increases of 2.4-fold ( < 0.05) and 2.6-fold ( < 0.01) at 10 mg/mL, respectively, compared to the control. Pancreatic islet cell assays showed a substantial proliferation effect, with up to a 57% increase at 50 µL/well, indicating potential protective properties against inflammation-induced cell loss. Notably, the smallest SPH peptide fraction (<1000 Da) exhibited GLP-1 agonist activity comparable to semaglutide, a widely used therapeutic agent, underscoring SPH's potential efficacy in modulating metabolic pathways. These results suggest that SPH not only enhances key incretin signaling but also promotes islet cell health, positioning it as a promising dietary intervention to improve age-related metabolic health, including the weight gain and underlying adverse metabolic changes frequently encountered through the menopause.
本研究考察了源自大西洋鲑（Salmo salar）的可溶性蛋白水解物（SPH）对肠促胰岛素受体活性和胰岛细胞保护的体外作用，以探索 SPH 对超重个体体重减轻和代谢健康的益处的潜在机制。SPH 表现出对胰高血糖素样肽-1（GLP-1）和胃抑制多肽（GIP）受体活性的剂量依赖性增强，与对照组相比，在 10mg/mL 时分别显著增加了 2.4 倍（<0.05）和 2.6 倍（<0.01）。胰岛细胞检测显示出显著的增殖作用，在 50μL/孔时最高增加了 57%，表明对炎症诱导的细胞损失具有潜在的保护特性。值得注意的是，最小的 SPH 肽片段（<1000Da）表现出与司美格鲁肽相当的 GLP-1 激动剂活性，司美格鲁肽是一种广泛使用的治疗剂，这突出了 SPH 在调节代谢途径方面的潜在功效。这些结果表明，SPH 不仅增强了关键的肠促胰岛素信号，还促进了胰岛细胞的健康，使其成为一种有前途的饮食干预措施，可改善与年龄相关的代谢健康，包括绝经后经常出现的体重增加和潜在的不良代谢变化。
